Study guide

7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring

Transplantation and Cellular Therapy Certified Nurse TCTCN

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The TCTCN Credential: Rename, Scope & Official Test Blueprint 1.2 TCTCN Eligibility, Test-Day Logistics, Scoring & Renewal 1.3 Building the Study Plan & Clinical Prioritization Framework 1.4 Clinical Triage Rehearsal & Exam-Day Question Strategy

2 Chapter 2: Foundations of Transplantation & Cellular Biology

2.1 Hematopoietic Lineage, the MHC & HLA Class I vs Class II Biology 2.2 HLA Typing Resolution, Donor Matching, DSA & ABO Compatibility 2.3 Disease Indications & the Cellular Therapy Modality Map 2.4 Pre-Transplant Risk Stratification & Organ Suitability Assessment 2.5 Stem Cell & Cellular Product Sources: Donor Selection Hierarchy 2.6 Conditioning Regimens & Lymphodepletion Principles 2.7 Recipient and Caregiver Education Across the Continuum

3 Chapter 3: Product Collection, Processing & Infusion Procedures

3.1 Stem Cell Mobilization: Niche Biology, Agents & CD34+ Collection Targets 3.2 Apheresis Nursing Care: Vascular Access, Citrate Toxicity & Donor Safety 3.3 Graft Engineering, ABO-Directed Processing & Cryopreservation Science 3.4 DMSO Toxicity, Premedication & Time-Critical Thawed Product Administration 3.5 Pre-Administration Verification, Equipment & CAR T Infusion Readiness 3.6 Infusion Monitoring & Acute Reaction Differential Management 3.7 Engraftment Definitions, Kinetics & Factors Impairing Recovery 3.8 Graft Failure Classification & Donor Chimerism Tracking

4 Chapter 4: Acute Post-HSCT Complications & Graft-versus-Host Disease

4.1 Acute GVHD: Billingham's Postulates, Classification & the Ferrara 3-Phase Model 4.2 Acute GVHD Organ Manifestations, Histopathology & MAGIC Staging 4.3 MAGIC Overall Grading & Acute GVHD Plasma Biomarkers 4.4 Acute GVHD Prophylaxis, First-Line Steroids & Steroid-Refractory Therapy 4.5 SOS/VOD: Microvascular Pathophysiology & Risk Stratification 4.6 SOS/VOD Diagnostic Criteria, Surveillance & Defibrotide Therapy 4.7 TA-TMA: Complement Pathophysiology, Harmonized Criteria & Differential 4.8 TA-TMA Management, Complement-Directed Therapy & Other Endothelial Syndromes

5 Chapter 5: Post-Transplant Infections & Supportive Care

5.1 Neutropenic Fever, Pre-Engraftment Phase & Empiric Antimicrobial Therapy 5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment 5.3 EBV/PTLD, HHV-6 Encephalitis, BK Cystitis, Adenovirus, HSV & VZV 5.4 Invasive Fungal Infections (Aspergillus, Candida, Mucor) & PJP Prophylaxis 5.5 Supportive Care in Aplasia: Transfusion Guidelines, Oral Mucositis & Nutrition

6 Chapter 6: Post-Cellular Therapy Management, CRS & ICANS

6.1 CAR Structural Architecture, Generations & Costimulatory Domain Biology 6.2 The Vein-to-Vein Lifecycle, In Vivo Kinetics & On-Target B-Cell Aplasia 6.3 CRS Pathophysiology, Clinical Kinetics & Inflammatory Biomarkers 6.4 ASTCT CRS Grading, Tocilizumab & Escalation Management 6.5 ICANS: Assessment, ICE Scoring & Clinical Management 6.6 Delayed Cellular Toxicities: Prolonged Cytopenias, B-Cell Aplasia & IEC-HS 6.7 Symptom Management and Functional Recovery After Cellular Therapy

7 Chapter 7: Chronic GVHD & Long-Term Survivorship

7.1 Chronic GVHD: Three-Phase Immunobiology & NIH Classification 7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring 7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy 7.4 Late Effects: Endocrine, Cardiovascular, Bone Health & Secondary Malignancies 7.5 Immune Reconstitution & the Inactivated Re-Vaccination Schedule 7.6 Live Vaccines, Household Contact Precautions & Survivorship Care Plans 7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment

8 Chapter 8: Quality of Life, Ethics & Professional Practice Standards

8.1 Psychosocial Trajectories, Distress Screening & Delirium Assessment 8.2 Caregiver Planning, Financial & Cultural Navigation, and Sexual Health 8.3 Palliative Care Integration, Advance Directives & Ethical Considerations 8.4 FACT-JACIE Quality Standards, CIBMTR / NMDP Reporting & Compliance 8.5 Evidence-Based Practice, Discharge Education & Quality Improvement

7.2 Chronic GVHD Diagnostic Manifestations, BOS & NIH Global Severity Scoring

Key Takeaways Explain This Topic AI

Diagnosis requires at least one NIH diagnostic manifestation, or a distinctive manifestation plus supportive biopsy, laboratory, specialist or radiographic evidence, after excluding infection, drug injury, malignancy and other mimics.

Diagnostic findings include specified skin sclerosis/poikiloderma/lichen-planus-like changes, oral lichen-planus-like change, esophageal web/stricture, fascia/joint contracture, genital lichen-planus/scarring, and qualifying BOS in the appropriate context; eyes and liver have no standalone diagnostic feature.

Clinical BOS uses obstruction and FEV1 decline, exclusion of infection, and supporting air trapping or another chronic-GVHD manifestation; biopsy may be needed when the lung is the only site.

NIH global severity is mild, moderate or severe from organ 0-3 scores, with lung involvement weighted more heavily; score attribution and longitudinal change guide care.

Last updated: September 2026

1. NIH Diagnostic and Distinctive Manifestations

A diagnostic manifestation can establish chronic GVHD by itself after alternatives are excluded. A distinctive manifestation is suggestive but requires pertinent biopsy, laboratory testing, specialist assessment, radiology, or chronic-GVHD evidence in the same or another organ.

Skin diagnostic: poikiloderma; lichen-planus-like, lichen-sclerosus-like, morphea-like, or deep sclerotic features. Depigmentation and papulosquamous lesions are distinctive. Erythema, maculopapular rash and pruritus occur in acute and chronic disease and are not diagnostic alone.

Mouth diagnostic: lichen-planus-like white/lacy changes. Xerostomia, mucoceles, atrophy, ulcers and pseudomembranes are distinctive. Isolated hyperkeratotic plaque/leukoplakia is not diagnostic and needs malignancy evaluation.

Eyes: dry/gritty/painful eye, cicatricial conjunctivitis, keratoconjunctivitis sicca and punctate keratopathy are distinctive, not standalone diagnostic findings. Ophthalmic examination helps attribution; Schirmer testing is not a universal severity score.

Esophagus/GI: esophageal web, stricture or upper-third narrowing is diagnostic. Anorexia, nausea, vomiting, diarrhea and weight loss are nonspecific and need evaluation for acute GVHD, infection, drugs and other causes.

Fascia/joints: fasciitis, groove sign, and stiffness/contracture secondary to sclerosis are diagnostic. Myositis/polymyositis is distinctive and requires confirmation.

Genital tract: NIH-specified lichen-planus-like features and scarring/stenosis are diagnostic; erosions, fissures and other symptoms need specialist attribution.

Liver: no standalone diagnostic or distinctive clinical feature; cholestatic or hepatitic tests require evaluation for drugs, viruses, iron, obstruction, SOS and other causes.

Bronchiolitis Obliterans Syndrome

BOS is an obstructive small-airway syndrome. Clinical NIH criteria use FEV1/VC below 0.70 or the fifth percentile, FEV1 below 75% predicted with at least 10% decline over less than two years, and absence of active respiratory infection. Supporting evidence is either another chronic-GVHD manifestation or air trapping/bronchiectasis on expiratory CT, RV over 120% predicted, or RV/TLC above the 90th percentile. If lung is the only involved site without a distinctive manifestation elsewhere, biopsy-proven bronchiolitis obliterans may be required to establish chronic GVHD for the NIH framework. Trend PFTs because early BOS may be asymptomatic.

2. NIH Organ Staging System (0 to 3 Scale)

Every organ system is scored individually on a validated scale from 0 (no involvement) to 3 (severe, functionally incapacitating involvement):

Organ system Score 0 Score 1 Score 2 Score 3

Skin No involvement ≤18% BSA without sclerotic features 19%–50% BSA or any movable superficial sclerosis >50% BSA or deep/non-movable sclerosis, impaired mobility, or ulceration

Mouth No symptoms Mild symptoms without significant oral-intake limitation Moderate symptoms with partial oral-intake limitation Severe symptoms with major oral-intake limitation

Eyes No symptoms Mild dry eye not affecting ADLs; lubricants ≤3 times/day Moderate dry eye partially affecting ADLs; lubricants >3 times/day or punctal plugs, without new vision impairment Severe dry eye significantly affecting ADLs/work or causing loss of vision

GI tract No symptoms Symptoms without significant weight loss (<5%) Symptoms with 5%–15% weight loss or moderate diarrhea Esophageal dilation, >15% weight loss, severe diarrhea, or major nutritional impairment

Liver Normal bilirubin and enzymes below scoring thresholds Normal bilirubin with ALT 3–5× ULN or AP ≥3× ULN Elevated bilirubin ≤3 mg/dL or ALT >5× ULN Bilirubin >3 mg/dL

Lungs FEV1 ≥80% predicted FEV1 60%–79% predicted FEV1 40%–59% predicted FEV1 ≤39% predicted

Joints/fascia No symptoms Mild tightness with normal or mildly decreased ROM and no ADL effect Tightness/contracture with moderate ROM loss and mild–moderate ADL limitation Contracture with severe ROM loss and significant ADL limitation

Genital tract No signs Mild signs/symptoms and minimal examination discomfort Moderate signs/symptoms with examination discomfort Severe signs/symptoms such as fusion or stenosis

3. Calculation of NIH Global Severity Score & Prognostic Utility

The NIH Global Severity Score combines the individual 0–3 organ scores into mild , moderate , or severe categories that standardize communication and inform risk and treatment planning; the category alone does not dictate one therapy: NIH GLOBAL SEVERITY SCORE ALGORITHM

  • +-------------------+-------------------------------------------------------------+
  • | Global Severity | Defining Organ Score Criteria |
  • +-------------------+-------------------------------------------------------------+
  • | MILD | * 1 or 2 organs involved with Score 1 |
  • | | * Lung score MUST be 0 |
  • +-------------------+-------------------------------------------------------------+
  • | MODERATE | * 3 or more organs involved with Score 1 |
  • | | * OR At least 1 organ involved with Score 2 |
  • | | * OR Lung Score = 1 |
  • +-------------------+-------------------------------------------------------------+
  • | SEVERE | * At least 1 organ involved with Score 3 |
  • | | * OR Lung Score = 2 or 3 |
  • +-------------------+-------------------------------------------------------------+
  • Clinical Management Implications

NIH organ and global severity scores standardize description and longitudinal response; they do not independently prescribe one drug or dose. Limited mild disease may be managed with organ-directed therapy and close follow-up. Moderate, severe, progressive, lung, or function-threatening disease often warrants systemic treatment plus organ-directed care, rehabilitation and infection/toxicity prevention. Distinguish reversible activity from fixed damage and incorporate rate of progression, prior therapy, comorbidity, infection, quality of life and patient goals.

Pulmonary involvement and severe global scores carry important morbidity and mortality risk. New cough, dyspnea or spirometric decline requires prompt evaluation for infection, bronchiolitis obliterans syndrome and non-GVHD pulmonary causes rather than waiting for a routine visit.

4. Assessing the Organs the Score Depends On

NIH organ scoring is only as good as the examination behind it, and the ocular and oral domains are the ones most often scored from a general impression rather than from a measurement.

Eyes. Dry eye in chronic GVHD ranges from mild grittiness to corneal ulceration and vision loss. Scoring uses the patient-reported severity of symptoms, the impact on activities of daily living, and whether lubricant drops are needed more than a defined number of times per day. Tear production may be measured objectively with a Schirmer test , and ophthalmology evaluation is arranged for anything beyond mild disease, because the eye can deteriorate faster than any other scored organ and the damage is not always reversible.

Mouth. Oral chronic GVHD produces lichenoid changes, erythema, ulceration, mucoceles, and restricted mouth opening. Scoring reflects the extent of mucosal change and the degree to which oral intake is limited. Assess for reduced mouth opening, dental caries from xerostomia, and pain that is limiting nutrition, and involve oral medicine or dentistry rather than treating it as a comfort issue alone.

Both domains illustrate the general rule of NIH scoring: it grades functional impact , not appearance, so the question is always what the patient can no longer do.